Inspire Medical (INSP) Q4 2025 earnings review
Profitability Surges, but Reimbursement Shock Hits Outlook
Inspire Medical delivered a solid Q4 with 12% revenue growth and record profitability, driven by the Inspire V launch and a massive one-time tax benefit. However, the narrative was derailed by a negative reimbursement update: the company received clarification that Inspire V procedures should use CPT code 64582 with a -52 modifier, likely reducing physician fees. Consequently, FY26 revenue guidance was set at 4-10% growth—significantly below the 'early indication' of 10-11% given in Q3—reflecting uncertainty and potential headwinds in the physician channel.
🐂 Bull Case
Gross margin expanded 160 bps YoY to 86.6%, and Adjusted EBITDA margin hit 29.5% in Q4 (up from 22% in 25Q3). The transition to Inspire V is driving significant manufacturing efficiencies and operating leverage.
Despite reimbursement noise, the product works. Early commercial data confirms a 20% reduction in surgical time and strong patient outcomes, which should sustain long-term demand once coding issues stabilize.
🐻 Bear Case
The requirement to use the -52 modifier (reduced service) for CPT 64582 creates immediate friction. Physicians face lower fees and coding uncertainty, which management admits impacts the Q1 outlook and necessitated the wider, lower FY26 guidance range.
FY26 revenue growth guidance of 4-10% marks a sharp deceleration from the 50% 5-year CAGR and 14% growth in FY25. The company is transitioning from a high-growth disruptor to a slower-growth mature med-tech profile.
⚖️ Verdict: 🔴
Bearish. While Q4 execution was strong, the reimbursement coding change is a structural negative that creates friction for implanters. The sharp deceleration in FY26 guidance (midpoint 7% vs prior expectation of >10%) fundamentally resets the growth narrative.
Key Themes
Coding Shock: The -52 Modifier
A major red flag emerged regarding billing. Clarification received just prior to earnings indicates Inspire V should be billed under CPT 64582 with a '-52 modifier' (signifying reduced service). Management admitted this creates 'coding uncertainty' and impacts physician fees. This negative surprise directly caused the widened and lowered FY26 revenue outlook (4-10% growth).
Record Profitability & Margins
Profitability metrics are accelerating rapidly. Gross margin reached a record 86.6% in Q4 (up 160 bps YoY), driven by the favorable sales mix of Inspire V. Adjusted EBITDA surged to $79.3M (29.5% margin), proving the business model can generate substantial cash flow ($117M operating cash flow for FY25) even as top-line growth moderates.
Operating Expense Discipline
Management demonstrated strong cost control. While revenue grew 12%, Operating Expenses grew only 9%. R&D expenses actually decreased YoY ($24.9M vs $30.3M), helping drive the Operating Income jump to $46.1M (+45% YoY). This discipline is critical given the single-digit revenue growth outlook.
Tax Benefit Distortion
GAAP Net Income was artificially inflated to $136.1M (EPS $4.66) due to an $85.8M tax benefit from releasing a valuation allowance. Investors must focus on Adjusted Net Income ($48.1M, EPS $1.65) to understand true earnings power. The optics of the 'beat' are heavily skewed by this accounting adjustment.
Inspire V Clinical Success
Operationally, the Inspire V launch is succeeding. Management confirmed the device is delivering on its promise of a 20% reduction in surgical time and strong outcomes (87% inspiratory overlap). This clinical efficiency is a key long-term driver, assuming the reimbursement friction can be resolved.
Competitive Coding Landscape
The prompt mentions legal expenses related to patent infringement suits with Nyxoah. While not a primary driver of Q4 results, the continued legal spend ($1.0M in Q4) and the need for a 'long-term solution' for a separate CPT code suggests the competitive and regulatory moat is facing pressure.
Other KPIs
Accelerating. Up 26% YoY from $62.7M in 24Q4. The margin expanded to 29.5%, demonstrating significant operating leverage despite the top-line deceleration.
Decelerating. Based on segment trends, U.S. growth is stabilizing around the low double-digits. The coding uncertainty creates risk for this core segment in early 2026.
Stable. Decreased from $516.5M at the start of the year, primarily due to $175M in share repurchases ($50M in Q4). The company is now self-funding through robust operating cash flow ($117M FY25).
Guidance
Decelerating. Implies 4% to 10% YoY growth, a sharp drop from the 14% growth achieved in FY25. The widened range specifically reflects the risk associated with the coding/billing uncertainty in Q1.
Decelerating vs Q4 run-rate. While FY25 Adjusted EPS was $2.42, the FY26 guide suggests a potential contraction or flat performance at the midpoint ($2.10). This likely reflects the full taxation impact (adj effective tax rate 26-28%) normalizing after the valuation allowance release.
Stable/Decelerating. FY25 achieved 7.3%. The guidance implies margins will remain flat, suggesting that the reimbursement headwinds and marketing investments may offset manufacturing efficiencies in the near term.
Key Questions
Magnitude of Reimbursement Hit
What is the specific percentage reduction in physician fees associated with the -52 modifier on CPT 64582 compared to the previous coding? How long do you expect this interim coding situation to persist?
Guidance Conservatism
The low end of FY26 guidance (4% growth) implies a severe slowdown. Does this assume a pause in center utilization due to the billing confusion, or are you seeing structural demand softening?
Long-Term CPT Strategy
You mentioned seeking a 'long-term solution' with a separate CPT code. What is the realistic timeline for this process—2027 or later—and what happens to margins in the interim?
Profitability vs. Growth
With growth slowing to single digits, will you pivot more aggressively to margin expansion to support the stock valuation, or is the plan to spend heavily to re-accelerate the top line?